Table 2.
Results of the cohort analyses
| Group | Patients (n) | Patient-years | Incident seizures (n) | Crude HR (95% CI) | Weighted HR (95% CI) |
|---|---|---|---|---|---|
| Primary analysis | |||||
| Follow up end by earlier of: outcome date, medication has been switched or discontinued, death, patient left practice or study end date | |||||
| Antipsychotic | 3923 | 11,914 | 65 | 1.59 (1.15–2.22) | 1.28 (0.74–2.19) |
| Psychotropica | 10,086 | 22,577 | 82 | 1 | 1 |
| Sensitivity analyses | |||||
| 1. Follow up end by earlier of: outcome date, death, patient left practice or study end date | |||||
| Antipsychotic | 3923 | 15,238 | 77 | 1.70 (1.26–2.30) | 1.40 (0.85–2.30) |
| Psychotropica | 10,086 | 30,306 | 94 | 1 | 1 |
| 2. Follow up end by earlier of: outcome date, death, patient left practice, study end date or 90 days after first continuous exposure | |||||
| Antipsychotic | 3923 | 8988 | 52 | 1.80 (1.23–2.65) | 1.36 (0.72–2.57) |
| Psychotropica | 10,086 | 15,601 | 55 | 1 | 1 |
aPsychotropic medication classes included were: antidepressants, stimulants and non-benzodiazepine hypnotics and anxiolytics